The stock has a 36-month beta value of 0.37. Opinions on the stock are mixed, with 4 analysts rating it as a “buy,” 1 as “overweight,” 8 as “hold,” and 1 as “sell.”
The public float for IONS is 134.02M, and at present, short sellers hold a 7.11% of that float. On May 09, 2024, the average trading volume of IONS was 1.09M shares.
IONS) stock’s latest price update
Ionis Pharmaceuticals Inc (NASDAQ: IONS)’s stock price has decreased by -1.88 compared to its previous closing price of 40.93. However, the company has seen a -6.63% decrease in its stock price over the last five trading sessions. Zacks Investment Research reported 2024-05-08 that Ionis (IONS) posts mixed first-quarter 2024 results. The company continues to focus on pipeline development.
IONS’s Market Performance
Ionis Pharmaceuticals Inc (IONS) has seen a -6.63% fall in stock performance for the week, with a -6.23% decline in the past month and a -18.93% plunge in the past quarter. The volatility ratio for the week is 2.84%, and the volatility levels for the past 30 days are at 2.63% for IONS. The simple moving average for the last 20 days is -3.92% for IONS stock, with a simple moving average of -11.50% for the last 200 days.
Analysts’ Opinion of IONS
Many brokerage firms have already submitted their reports for IONS stocks, with Wolfe Research repeating the rating for IONS by listing it as a “Outperform.” The predicted price for IONS in the upcoming period, according to Wolfe Research is $58 based on the research report published on April 10, 2024 of the current year 2024.
BofA Securities, on the other hand, stated in their research note that they expect to see IONS reach a price target of $62, previously predicting the price at $52. The rating they have provided for IONS stocks is “Buy” according to the report published on January 02nd, 2024.
BofA Securities gave a rating of “Neutral” to IONS, setting the target price at $52 in the report published on October 23rd of the previous year.
IONS Trading at -6.49% from the 50-Day Moving Average
After a stumble in the market that brought IONS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -26.24% of loss for the given period.
Volatility was left at 2.63%, however, over the last 30 days, the volatility rate increased by 2.84%, as shares sank -6.47% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -15.29% lower at present.
During the last 5 trading sessions, IONS fell by -6.63%, which changed the moving average for the period of 200-days by +2.34% in comparison to the 20-day moving average, which settled at $41.66. In addition, Ionis Pharmaceuticals Inc saw -20.62% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IONS starting from KLEIN JOSEPH III, who sale 6,000 shares at the price of $42.71 back on May 03 ’24. After this action, KLEIN JOSEPH III now owns 0 shares of Ionis Pharmaceuticals Inc, valued at $256,277 using the latest closing price.
Baroldi Joseph, the EVP, Chief Business Officer of Ionis Pharmaceuticals Inc, sale 4,006 shares at $41.60 during a trade that took place back on Apr 16 ’24, which means that Baroldi Joseph is holding 19,631 shares at $166,641 based on the most recent closing price.
Stock Fundamentals for IONS
Current profitability levels for the company are sitting at:
- -0.45 for the present operating margin
- 0.99 for the gross margin
The net margin for Ionis Pharmaceuticals Inc stands at -0.46. The total capital return value is set at -0.14. Equity return is now at value -98.20, with -13.61 for asset returns.
Based on Ionis Pharmaceuticals Inc (IONS), the company’s capital structure generated 0.79 points at debt to capital in total, while cash flow to debt ratio is standing at -0.21. The debt to equity ratio resting at 3.76. The interest coverage ratio of the stock is -4.86.
Currently, EBITDA for the company is -322.84 million with net debt to EBITDA at -3.76. When we switch over and look at the enterprise to sales, we see a ratio of 8.78. The receivables turnover for the company is 8.05for trailing twelve months and the total asset turnover is 0.26. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.37.
Conclusion
To sum up, Ionis Pharmaceuticals Inc (IONS) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
